GEORGE N. KARACHALIOS, M.D.; JOHN G. PARIGORAKIS, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Sulindac is a nonsteroidal anti-inflammatory and analgesic drug that is now used extensively in the treatment of various forms of rheumatic disease. Several reports of adverse reactions, such as hepatotoxicity, Stevens-Johnson syndrome, aplastic anemia, and hypersensitivity, have been noted (1, 2). We report a case in which a severe thrombocytopenic reaction was associated with the use of sulindac.
A 67-year-old woman presented with a painful shoulder and right knee in March 1982. History and physical findings were consistent with osteoarthritis, and treatment was started with diclofenac sodium for 1 month without effect. On 15 May, diclofenac sodium
KARACHALIOS GN, PARIGORAKIS JG. Thrombocytopenia and Sulindac. Ann Intern Med. ;104:128. doi: 10.7326/0003-4819-104-1-128_2
Download citation file:
Published: Ann Intern Med. 1986;104(1):128.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use